Careers   |    Contact   |    Directions   |    Site Map   |    Search
Home  |  Company  |  Our Team  |  Programs  |  Publications  |  News & Events
EnVivo News & Events EnVivo Pharmaceuticals announced today that it has initiated a clinical safety and biomarker study of its alpha-7 nicotinic agonist (EVP-6124) in Schizophrenia patients chronically treated with atypical antipsychotic medications. Montreal, Quebec and Watertown, MA. February 6, 2008 - MethylGene Inc. (TSX:MYG) and EnVivo Pharmaceuticals today announced that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005.
© 2005 EnVivo Pharmaceuticals. All Rights Reserved.